-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Cardiovascular outcome trials (CVOTs) conducted in patients with type 2 diabetes mellitus (T2D) over the past few years have shown that GLP-1 agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) reduce the risk of
Recent guidelines recommend starting GLP-1 RA or SGLT-2i in patients at high cardiovascular risk or in patients with confirmed atherosclerotic cardiovascular disease, regardless of baseline glycosylated hemoglobin levels
Objective: In this study, we analyzed the efficacy and safety
Methods: Using a linkable managed health database, we included patients aged 50 years and older who
Results: The analysis included 20,762 patients
Figure 1 matches the number of events and the risk-to-risk ratio of death and clinical outcomes in the population according to treatment status (CI 95%) (ITT analysis
Figure 2: Event number and risk ratio of deaths and clinical outcomes in a matched population without prior cardiovascular disease (CI 95%)
Table 1 Number of events and risk ratios of people matching deaths and clinical outcomes according to treatment status (PP analysis) (CI 95%)
Table 2 Frequency of serious adverse events by treatment status from 2015 to 2019
GLP-1RA has shown to be as secure and more effective
Source: Baviera M, Foresta A, Colacioppo P,et al.
